Business Wire

CA-ULTRAVIOLET-DEVICES

Share
UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet (3.65 Meters) Distance in 5 Minutes

UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10 , inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters). Testing on the coronavirus strain that causes the COVID-19 disease was conducted by Innovative Bioanalysis, a CAP, CLIA, and BEI-recognized BSL-3 certified laboratory (CA, USA). The Centers for Disease Control and Prevention (CDC) has indicated that the COVID-19 disease can be spread by both surface and airborne transmission of SARS-CoV-2.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005585/en/

The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals. The UVDI-360 Room Sanitizer has previously been proven to help prevent Healthcare-Associated Infections and to inactivate over 35 pathogens, including human coronavirus (229E), in over 10 peer-reviewed published clinical studies and independent laboratory testing.

“We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.” stated Peter Veloz, Chief Executive Officer, UVDI. “Specific to use in hospitals for whole room disinfection, we believe that proving rapid inactivation of pathogens at distances of 8 feet (2.44 meters) and 12 feet (3.65 meters) is the best marker for in-facility performance. Independent confirmation of effectiveness against high-risk pathogens is a common sense, yet critical step to verify disinfecting claims for UV devices.”

“Building on our deep science-based evidence demonstrating the UVDI-360’s effectiveness against high-risk pathogens, including coronaviruses, we feel the healthcare professionals we serve globally deserve proof against the specific SARS-CoV-2 viral strain causing COVID-19,” added Dr. Ashish Mathur, Vice President of Innovation and Technology, UVDI.

About UltraViolet Devices, Inc.

UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California, applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate high-risk pathogens. UVDI’s proven Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).

1 https://www.cdc.gov/coronavirus

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI20.11.2025 15:17:00 CET | Press release

Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120130113/en/ K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adoption of K Pro Free, as well as the co-organization of communication and dissemination initiatives around the use of AI in health. In this way, the partnership will promote user training, but also enrich and continuously improve the co-pilot's models through feedback and use cases from the l’Université Paris-Saclay community. This partnership is part of Université Paris-Saclay’s strategy to integr

Frasca Advances Flight Training Technology with New Visual System Powered by Unreal Engine20.11.2025 15:05:00 CET | Press release

Frasca International, Inc., a FlightSafety International company and leader in flight simulation, today announced the launch of VITAL FVS 100, the next evolution of its visual system technology. Building on the proven TruVision Global platform, VITAL FVS 100 was developed using Epic Games’ Unreal Engine and delivers unprecedented realism, scalability, and innovation in pilot training. The Unreal-powered VITAL FVS 100 system introduces major advancements in visual fidelity and training realism, further enhancing the capabilities of Frasca, a leading developer of flight simulators and training devices. The new system includes physically based renderings, advanced lighting effects, and a new volumetric cloud model that creates dynamic, weather-rich environments. Terrain imagery now includes one-meter resolution coverage for the contiguous United States and Hawaii, with expanded global datasets covering European buildings and tree covered regions. Additionally, enhanced particle effects re

GigaOm Radar for Vector Databases v3 Positions Vespa.ai as a Leader and Outperformer20.11.2025 15:00:00 CET | Press release

Vespa Recognized for Integrated Ranking, Multimodal Search, and Production-Scale AI Performance Vespa.ai, the creator of the AI Search Platform for building and deploying large-scale, real-time AI applications powered by big data, today announced its recognition as a Leader and Outperformer in the GigaOm Radar for Vector Databases v3, marking the company’s third consecutive year being evaluated in GigaOm’s vector database research. Now in its third edition, the report compares 17 leading open source and commercial solutions using GigaOm’s structured evaluation framework. In addition to core table-stakes capabilities, the Radar reviews each vendor’s key features, emerging strengths, and broader business criteria. The shift from Sonar to Radar reflects the technology’s transition into mainstream adoption. GigaOm names Vespa.ai a leader for its ability to manage complex data, optimize results at scale, and support multimodal AI workloads. The report highlights Vespa’s native tensor suppor

Hitit Empowers Airlines to Optimize Crew Leave Planning with Gurobi20.11.2025 15:00:00 CET | Press release

With Crane Crew, one of the products in Hitit’s Crane Solution Suite, dozens of airlines have reduced their planning periods from weeks to minutes. Gurobi Optimization, LLC, the leader in decision intelligence technology, is proud to be the solver of choice for Hitit, a leading global provider of airline and travel IT solutions. Hitit’s Crane Crew Leave Optimizer—one of the key sub-modules of Hitit’s Crane Crew solution—enables airlines to quickly generate optimal leave schedules for thousands of crew members. Powered by Gurobi’s mathematical optimization solver, the tool significantly reduces planning time while improving both operational efficiency and crew satisfaction. Among the many constraints that airlines must consider are operational requirements, business rules, crew seniority, and personal preferences. As such, manual planning efforts can often lead to inefficiencies, crew dissatisfaction, and compliance risks. After switching to Crane Crew, Hitit’s partner airlines have rep

Myonex Appoints Greg Lavin as Chief Executive Officer20.11.2025 15:00:00 CET | Press release

Greg Lavin takes over the CEO role as James Lovett retires and joins the company’s Board of Directors Myonex®, a leading global integrated clinical trial supply solutions and commercial services company, announced today that Greg Lavin, Chief Financial Officer (CFO), will assume the role of Chief Executive Officer (CEO) effective January 1, 2026. A seasoned executive with experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical and laboratory services, and healthcare data analysis, Lavin succeeds James Lovett, who is retiring and will remain on the company’s board of directors to provide strategic guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120250133/en/ Greg Lavin at Myonex's Headquarters in Horsham, PA During his 6-plus years as CFO of Myonex, Lavin has worked closely with Lovett in driving its transformation from a comparator sourcing su

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye